FDA granted AstraZeneca an accelerated approval for camizestrant (an oral selective estrogen receptor degrader, or SERD) in certain breast cancer patients, despite a negative advisory committee vote earlier this year. The decision marks a regulatory milestone for oral endocrine options that aim to degrade ER rather than merely block it. For AstraZeneca, the approval underscores continued investor and clinical momentum for next-generation SERDs that target established ER-positive disease settings where resistance remains a persistent challenge. The accelerated pathway means confirmatory study performance will remain central to the next regulatory step. Clinicians and trial teams will now align treatment sequencing and future evidence generation around the accelerated label while they await additional data that could determine full approval and potentially broaden indications.